PCM
IMCR icon

Pentwater Capital Management’s Immunocore IMCR Stock Holding History

Pentwater Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$508K – 103
2024
Q2 		$508K Hold
15,000
– – 0.01% 85
2024
Q1 		$975K Buy
+15,000
New +$1.03M 0.01% 87

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pentwater Capital Management's IMCR Position: Q3 2024 in Review

Pentwater Capital Management sold out of Immunocore (IMCR) in Q3 2024, closing a stake of 15,000 shares — an estimated $508K sold.

Pentwater Capital Management first reported a position in IMCR in Q1 2024 and held it in 2 quarters. The position peaked at $975K in Q1 2024. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2024.

  • Pentwater Capital Management reported no remaining Immunocore position as of Q3 2024 after selling out during the quarter.
  • Pentwater Capital Management sold 15,000 Immunocore shares in Q3 2024, an estimated $508K.
  • Pentwater Capital Management first reported a position in Immunocore in Q1 2024 and held it in 2 quarters.
  • Pentwater Capital Management's Immunocore position peaked at $975K in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Immunocore as of Q3 2024.

Based on Pentwater Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.